---
category: news
title: "Inhibrx, Sanofi ratify $2.2B deal for AATD therapy"
excerpt: "Inhibrx Inc. and Sanofi SA have agreed to a deal worth up to $2.2 billion, whereby the latterâ€™s Aventis Inc. subsidiary will acquire INBRX-101, an optimized, recombinant alpha-1 antitrypsin (AAT) augmentation therapy undergoing a registrational trial for ..."
publishedDateTime: 2024-01-22T23:59:00Z
originalUrl: "https://www.bioworld.com/articles/704871-inhibrx-sanofi-ratify-22b-deal-for-aatd-therapy"
webUrl: "https://www.bioworld.com/articles/704871-inhibrx-sanofi-ratify-22b-deal-for-aatd-therapy"
type: article

provider:
  name: BioWorld
  domain: bioworld.com

topics:
  - AI in Healthcare
  - AI

secured: "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;Buk9D63fkV3vDdVNR1RB4A=="
---

